Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opdivo And Eliquis Carry Bristol’s Q1; Company Continues To Defend IO Strategy

Executive Summary

Novel oral anticoagulant Eliquis (apixaban) brought in $1.5bn in the first quarter and is set to overtake warfarin later this year. But Bristol remains on the defense on IO after a disappointing AACR.

You may also be interested in...



Novartis' Growth Driver Tafinlar/Mekinist Picks Up New Melanoma, Thyroid Indications

New FDA labeling brings Tafinlar/Mekinist into adjuvant melanoma setting, but Bristol's competing Opdivo already has captured nearly 50% of the market and is approved regardless of genetic mutation.

Merck Files Keytruda/Chemo Combo Early With FDA In 1L Squamous Lung Cancer

Also, Bristol has filed its Opdivo/Yervoy IO combination in Europe for first-line NSCLC, including squamous and non-squamous disease, based on CheckMate 227 data; some analysts expect FDA will accept the same dataset.

Merck's Keytruda Keeps Nipping At Opdivo's Heels

In the US there are more new starts on Keytruda than any other immunotherapy, Merck says in first-quarter earnings report.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel